Ignyta Appoints Jerry Hurst to Executive Advisory Board

  Ignyta Appoints Jerry Hurst to Executive Advisory Board

Business Wire

SAN DIEGO -- February 15, 2013

Ignyta, Inc., the personalized medicine company dedicated to improving the
diagnosis and treatment of patients with rheumatoid arthritis, lupus and other
autoimmune diseases, announced today the appointment of Jerry Hurst, a veteran
of CLIA lab operations and former manger of the state of California’s CLIA lab
inspection program, to its Executive Advisory Board.

“As Ignyta prepares to establish a leading CLIA lab to perform diagnostic
services for autoimmune disease, we are assembling a team with proven track
records in successful laboratory development, licensure and operations,” said
Jonathan Lim, M.D., co-founder, chairman and CEO of Ignyta. “With over 30
years of experience in clinical laboratory science, including as manager of
the state of California’s CLIA inspection program, and his subsequent
involvement in the establishment of multiple commercial CLIA labs, Jerry has
an unmatched understanding of what is required to successfully develop and
operate a CLIA lab.”

“I am passionate about bringing to bear my experience from many years managing
the California CLIA inspection program to help innovative diagnostic companies
establish high performing CLIA labs that comply with all state and federal
regulations,” said Mr. Hurst. “Ignyta has a very promising technology platform
and approach that has potential to provide meaningful benefit, through early
disease detection, to patients suffering from autoimmune disease.”

Jerry Hurst is a certified public health microbiologist who has worked as a
licensed Clinical Laboratory Scientist in all specialties (e.g., hematology,
chemistry, immunohematology, microbiology, toxicology, immunology). He worked
in the California laboratory regulatory agency (Laboratory Field Services) as
an inspector, eventually managing the California and federal CLIA inspection
programs statewide, the HIV approval program, the Examiner training program,
and the laboratory complaint program. Subsequent work in the private sector
included Administrative Laboratory Director of Hayward and Fremont Kaiser
Hospitals, Vice President for Regulatory Affairs at Unilab Corporation, and
Laboratory Director of the Humboldt and Fresno Public Health Laboratories.

He currently assists laboratories and organizations seeking new clinical
laboratory licensure, CLIA certification, and/or accreditation. This work
includes developing applicable validation studies for Laboratory Developed
Tests, establishing and implementing required infrastructure along with
applicable procedures, and assisting in the development of appropriate
corrective action plans to address federal/state citations. National and
international clients include large and small clinical laboratories,
biotechnology companies, state and county public health laboratories, private
attorneys, the U.S. Department of Justice, and research laboratories.

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a personalized medicine
company developing revolutionary new products and services to customize
diagnosis and treatment of patients with rheumatoid arthritis, lupus and other
autoimmune diseases.

The company was launched in August 2011 by Jonathan E. Lim, M.D., former
president, CEO, and board director of Halozyme Therapeutics, Inc., and Gary S.
Firestein, M.D., director of the Clinical and Translational Research Institute
and Dean and Associate Vice Chancellor of Translational Medicine at UC San
Diego. Ignyta is a trailblazer in the application of “omics” technologies
integrated with bioinformatics to the development and commercialization of
novel biomarkers and tests for diagnostic and therapeutic applications in
autoimmune diseases.

The scientific discoveries that fueled the founding of Ignyta were published
in July 2012 in the Annals of the Rheumatic Diseases (http://bit.ly/QOZ8Zr).
In 2012, the company successfully closed a $5.5 million Series B financing led
by City Hill Ventures, LLC (http://www.cityhillventures.com/) and Colt
Ventures (http://www.coltventures.com/), and a $500,000 capital term loan from
Silicon Valley Bank (http://www.svb.com/). For more information, please visit:


Media and Investor Contact:
Zachary Hornby, 858-369-5732
Press spacebar to pause and continue. Press esc to stop.